National Kidney Foundation and Ardelyx, Inc. survey finds dialysis patients struggle to maintain serum phosphorus levels

National Kidney Foundation and Ardelyx, Inc. survey finds dialysis patients struggle to maintain serum phosphorus levels

Most respondents ask for new treatments to help control phosphorus levels

Waltham, Mass. Y NEW YORK, November 4, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX) in partnership with the National Kidney Foundation (NKF), today announced the results of a survey of patients with chronic kidney disease (CKD) on dialysis conducted to better understand patient experience in managing serum phosphorus levels. The survey found that more than 80% of respondents struggle to control their serum phosphorus levels, with more than 90% citing the need for new treatment options.

“Despite best efforts with current treatment strategies, a significant proportion of patients have persistent hyperphosphatemia, placing them at increased risk for complications from bone and mineral disorders, including vascular disease,” he said. Jose Vassalotti, MD, medical director of the National Kidney Foundation. “The results of this survey point to the difficulty that people living with kidney disease on dialysis have in coping with the current low-phosphorus diet and medication schedules.”

“We are proud to bring the voice of the patient to this important conversation,” said Laura Williams, MD, medical director of Ardelyx. “The idea for this survey, which was born out of the Ardelyx Patient Advisory Council, provides great insight into the challenges patients face in managing hyperphosphatemia and supports the need to innovate in this space. As a company committed to putting patients First and foremost, and as a CKD patient, we are proud of this collaborative effort that truly captures the voice of kidney disease patients on dialysis.”

Hyperphosphatemia is a serious condition resulting in an abnormally high level of phosphorus in the blood that is estimated to affect more than 745,000 dialysis patients in major developed countries. Currently, dialysis patients are often prescribed phosphate binders, the only class of medication currently available to treat hyperphosphatemia and control elevated serum phosphorus levels, requiring very frequent dosing of several large pills several times a day. day with meals.

The survey results reveal the daily burden dialysis patients face when, in collaboration with their physicians, trying to manage their serum phosphorus levels, including:

  • Only 18% of patients reported consistently keeping their phosphorus within the monthly range
  • 89% found that it takes effort to control their phosphorus, and 86% reported at least some difficulty following a low-phosphorus diet.
  • Eighty-eight percent reported at least some difficulty taking phosphate binders, and 60% reported side effects from their phosphate binder pills, including nausea, diarrhea, constipation, and vomiting.
  • 92% noted the need for a better way to manage their phosphorous levels.

The survey, a collaborative effort, conducted by the National Kidney Foundation and sponsored by the Ardelyx, Inc. Patient Advisory Council, was conducted online among September 28, 2022October 8, 2022who evaluated 475 dialysis patients who are currently prescribed phosphate binders and take an average of seven binders per day participated in the survey.

The full results of the survey will be presented during an upcoming webinar. please visit for additional information on hyperphosphatemia.

About the National Kidney Foundation

The National Kidney Foundation (NKF) is the largest, longest-standing, and most comprehensive patient-focused organization dedicated to kidney disease awareness, prevention, and treatment in the US. To learn more about NKF, visit

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative world-class medicines that fill significant unmet medical needs. Ardelyx’s first approved product, IBSRELA® (tenapanor) is available in the United States Y Canada. Ardelyx is developing XPHOZAH® (tenapanor), a new candidate product to control serum phosphorus in adult CKD patients on dialysis, which has successfully completed three Phase 3 trials. Ardelyx has a Phase 2 potassium-lowering compound, RDX013, for the potential treatment of elevated serum potassium or hyperkalaemia, a problem among certain patients with kidney and/or heart disease, and an early stage program in metabolic acidosis, a serious electrolyte disturbance in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in JapanFosun Pharma in Porcelain and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

SOURCE Ardelyx

Leave a Comment